Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines — StellaPhase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(15 sites)
China
Peking Union Medical College Hospital, Beijing, Beijing Municipality Peking University First Hospital, Beijing, Beijing Municipality Peking University Third Hospital, Beijing, Beijing Municipality The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong The First Hospital of Hebei Medical University, Shijiazhuang, Hebei The Third Xiangya Hospital of Central South University, Changsha, Hunan The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Huashan Hospital, Fudan University, Shanghai, Shanghai Municipality Xianyang Hospital of Yan'an University, Xianyang, Shanxi West China Hospital, Sichuan University, Chengdu, Sichuan Tianjin Medical University General Hospital, Tianjin, Tianjin Municipality Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang Last updated September 2025